deltatrials
Unknown PHASE1 NCT00003633

Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer

Treatment of Prostate Cancer by Induction of Alternate Cell Death Pathways: A Phase I Trial of Docetaxel, Estramustine, Mitoxantrone and Prednisone

Sponsor: Herbert Irving Comprehensive Cancer Center

Conditions Prostate Cancer
Interventions docetaxel estramustine phosphate sodium mitoxantrone hydrochloride prednisone
Updated 5 times since 2017 Last updated: Dec 18, 2013 Started: Aug 31, 1998

This PHASE1 trial investigates Prostate Cancer and is currently ongoing. Herbert Irving Comprehensive Cancer Center leads this study, which shows 5 recorded versions since 1998 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE1

    Status: Unknown Status → Unknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE1

  5. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE1

    First recorded

Aug 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Herbert Irving Comprehensive Cancer Center
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • New York, United States